Edition:
India

Assertio Therapeutics Inc (ASRT.OQ)

ASRT.OQ on NASDAQ Stock Exchange Global Select Market

0.73USD
18 Sep 2020
Change (% chg)

$-0.00 (-0.56%)
Prev Close
$0.74
Open
$0.75
Day's High
$0.76
Day's Low
$0.72
Volume
103,080
Avg. Vol
267,882
52-wk High
$1.70
52-wk Low
$0.55

Latest Key Developments (Source: Significant Developments)

Assertio Therapeutics Says Qtrly GAAP Total Revenues $57.2 Mln
Thursday, 8 Aug 2019 

Aug 7 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES STRONG SECOND-QUARTER 2019 RESULTS.CONFIRMS 2019 EARNINGS GUIDANCE RANGE AND ADJUSTS NEUROLOGY FRANCHISE NET SALES GUIDANCE.QTRLY GAAP TOTAL REVENUES $57.2 MILLION.QTRLY NON-GAAP TOTAL REVENUES $59.3 MILLION.QTRLY GAAP LOSS PER SHARE $0.21.QTRLY ADJUSTED EARNINGS PER SHARE $0.25.SEES 2019 NEUROLOGY FRANCHISE NET SALES LOW-SINGLE DIGIT GROWTH.Q2 EARNINGS PER SHARE VIEW $0.25, REVENUE VIEW $59.0 MILLION -- REFINITIV IBES DATA.  Full Article

Assertio Therapeutics Reports Qtrly Adjusted Earnings Per Share $0.23
Thursday, 9 May 2019 

May 8 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES FIRST-QUARTER 2019 FINANCIAL RESULTS.ASSERTIO THERAPEUTICS INC - RAISES 2019 EARNINGS GUIDANCE RANGE AND CONFIRMS NEUROLOGY FRANCHISE NET SALES GUIDANCE.ASSERTIO THERAPEUTICS INC - REPORTS QTRLY NEUROLOGY FRANCHISE NET SALES OF $26.3 MILLION.ASSERTIO THERAPEUTICS INC - QTRLY COMMERCIALIZATION AGREEMENT REVENUES OF $30.9 MILLION.ASSERTIO THERAPEUTICS INC - TOTAL QTRLY REVENUES $57.9 MILLION.ASSERTIO THERAPEUTICS INC - QTRLY TOTAL NON-GAAP REVENUE $59.7 MILLION.ASSERTIO THERAPEUTICS INC - QTRLY GAAP LOSS PER SHARE $0.22.ASSERTIO THERAPEUTICS INC - QTRLY ADJUSTED EARNINGS PER SHARE $0.23.ASSERTIO THERAPEUTICS INC - AS OF MARCH 31, 2019, COMPANY HAD CASH AND CASH EQUIVALENTS OF $109.7 MILLION.ASSERTIO THERAPEUTICS INC - SEES 2019 NEUROLOGY FRANCHISE NET SALES LOW TO MID-SINGLE DIGIT GROWTH.ASSERTIO THERAPEUTICS INC - SEES 2019 GAAP NET LOSS $68 MILLION TO $58 MILLION.ASSERTIO THERAPEUTICS INC - SEES 2019 ADJUSTED EBITDA $118 MILLION TO $128 MILLION.  Full Article

Assertio Therapeutics Announces Favorable NUCYNTA Patent Ruling
Thursday, 28 Mar 2019 

March 28 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES FAVORABLE NUCYNTA® PATENT RULING.ASSERTIO THERAPEUTICS - BASED ON COLLEGIUM'S CURRENT 2019 NUCYNTA FRANCHISE REVENUE GUIDANCE, CO EXPECTS SUCH ROYALTIES TO BE ABOUT $120 MILLION IN 2019.ASSERTIO THERAPEUTICS - WITH U.S. COURT'S RULING, CO EXPECTS MARKET EXCLUSIVITY UNTIL DEC. 2025 FOR NUCYNTA ER, NUCYNTA AND NUCYNTA ORAL SOLUTION.  Full Article

Assertio Therapeutics Announces Fourth-Quarter And Full-Year 2018 Financial Results
Thursday, 7 Mar 2019 

March 6 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.FILES NDA FOR LONG-ACTING COSYNTROPIN AND RECEIVES FDA NOTIFICATION OF ACCEPTANCE.ISSUES FULL-YEAR 2019 GUIDANCE FOR EARNINGS AND NEUROLOGY FRANCHISE NET SALES.ISSUES FULL-YEAR 2019 GUIDANCE FOR EARNINGS AND NEUROLOGY FRANCHISE NET SALES.QTRLY GAAP LOSS PER SHARE $0.38.SEES 2019 NEUROLOGY FRANCHISE NET SALES LOW-TO MID-SINGLE DIGIT GROWTH.QTRLY ADJUSTED EARNINGS PER SHARE $0.30.QTRLY TOTAL REVENUES $42.6 MILLION & NON-GAAP REVENUE $62.8 MILLION.SEES 2019 NON-GAAP ADJUSTED EBITDA $115 TO $125 MILLION.Q4 EARNINGS PER SHARE VIEW $0.20, REVENUE VIEW $60.9 MILLION -- REFINITIV IBES DATA.Q4 REVENUE VIEW $60.9 MILLION -- REFINITIV IBES DATA.SEES 2019 GAAP NET LOSS $71 MILLION TO $61 MILLION.Q4 INCLUDES A $21.3 MILLION ADJUSTMENT REVERSAL FOR NON-CASH VALUE ASSIGNED TO INVENTORY TRANSFERRED TO COLLEGIUM.  Full Article

Assertio Therapeutics Announces Amendment Of Its Senior Secured Credit Facility
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES AMENDMENT OF ITS SENIOR SECURED CREDIT FACILITY.ASSERTIO THERAPEUTICS INC - WILL ADD A TRAILING FOUR-QUARTER NET SALES COVENANT OF $195 MILLION.ASSERTIO THERAPEUTICS - AMENDED SENIOR SECURED CREDIT FACILITY WITH NEW TRAILING 12-MONTH DEBT-TO-ADJUSTED EBITDA RATIO THAT DECLINES OVER TIME.  Full Article

Assertio Therapeutics Inc Sees 2018 GAAP Net Income Of $40 Mln To $50 Mln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS INC - SEES 2018 GAAP NET INCOME OF $40 MILLION - $50 MILLION AND 2018 ADJUSTED EBITDA OF $145 MILLION - $155 MILLION - SEC FILING.  Full Article

Assertio Therapeutics Announces Submission Of NDA For FDA Approval Of Cosyntropin Depot
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Assertio Therapeutics Inc ::ASSERTIO THERAPEUTICS ANNOUNCES SUBMISSION OF NDA FOR FDA APPROVAL OF COSYNTROPIN DEPOT.ASSERTIO THERAPEUTICS - IF NDA SUCCESSFUL, WILL OFFER PATIENTS IN U.S. ALTERNATIVE DEPOT FORMULATION TO IMMEDIATE-RELEASE COSYNTROPIN BY EARLY 2020.  Full Article

BRIEF-Assertio Completes Merger With Zyla Life Sciences

* ASSERTIO COMPLETED MERGER WITH ZYLA LIFE SCIENCES Source text for Eikon: Further company coverage: